DHA phase II sbir contract for psoralen-UV-a inactivation based high-throughput pathogen inactivation device

Active Definitive Contract Awarded Last action

Contract number
HT942525C0029
Awardee
Awarding agency
Obligated
$1,299,966

Award facts

Contract value 100% obligated
$1,299,965.51 Current and potential, with all options
Completion date 57% complete
Current and potential, with all options
Contracting staff
Set-aside
Total Small Business
Competition
Full and Open Competition after exclusion of sources · 3 offers Negotiated Proposal / Quote
Pricing
Firm Fixed Price
Place of performance
Golden, CO, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00003 $0
Supplemental Agreement for work within scope P00002 $0
Other Administrative Action P00001 · Psoralen-UV-a inactivation based high-throughput pathogen inactivation device $0
Original award $1,299,966

About this award

The Defense Health Agency awarded a $1,299,965.51 definitive contract to TDA Research, Inc. for development of a psoralen-UV-A inactivation-based high-throughput pathogen inactivation device on July 11, 2025, under a total small business set-away. The contract carries a firm fixed price structure and an ultimate completion date of November 10, 2027.

The originating solicitation describes a Phase II SBIR effort for a psoralen-UV-A inactivation device capable of high-throughput pathogen processing. Place of performance is Golden, Colorado. TDA Research, Inc. is a small business prime contractor headquartered in Golden and specializes in advanced materials science, chemical engineering, and medical device research and development almost exclusively through SBIR and STTR vehicles. Colorado State University, acting through its Sponsored Programs division, performs subcontract work assisting with research and development of the device and regulatory planning.

Subawards

Subcontractor Amount Awarded
Subcontractor not on record DHA PHASE II SBIR CONTRACT FOR PSORALEN-UV-A INACTIVATION BASED HIGH-THROUGHPUT PATHOGEN INACTIVATION DEVICE Psoralen–UV-A Inactivation Device Regulatory Plan $83,238
Colorado State University DHA PHASE II SBIR CONTRACT FOR PSORALEN-UV-A INACTIVATION BASED HIGH-THROUGHPUT PATHOGEN INACTIVATION DEVICE Assisting with research to develop… $372,003

Quick answers

Who was awarded contract HT942525C0029?

HT942525C0029 was awarded to TDA Research, Inc. by Defense Health Agency (Department of Defense) on July 11, 2025.

How much is contract HT942525C0029 worth?

The government has obligated $1,299,966 on HT942525C0029.

Was contract HT942525C0029 competed?

The extent of competition for HT942525C0029 was full and open competition after exclusion of sources. The government received 3 offers. It was set aside: Total Small Business.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award